| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 9, 2023 |
| Accession Number: | 0001385508-23-000095 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2021 | $42.00 | Outperform | Oppenheimer |
Oppenheimer initiated coverage of Opiant Pharmaceuticals with a rating of Outperform and set a new price target of $42.00
4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
15-12G - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (ORIG-1) with active ingredient NALMEFENE has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form
For Immediate Release: May 22, 2023 Today, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This is the first FDA approval of nalmefene hydrochloride nasal spray for health care and community use. “The agency continues to advance the FDA
Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (nalmefene) (ORIG-1) with active ingredient OPVEE (nalmefene) has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form
SC 13G/A - OPIANT PHARMACEUTICALS, INC. (0001385508) (Subject)
SC 13G - OPIANT PHARMACEUTICALS, INC. (0001385508) (Subject)
SC 13D/A - OPIANT PHARMACEUTICALS, INC. (0001385508) (Subject)
Indivior to acquire Opiant Pharmaceuticals for total consideration of $28.00 per share comprising of an upfront cash payment of $20.00 per share at closing plus contingent value rights (CVRs) worth up to $8.00 per share in cash, payable on achievement of certain net revenue thresholds for OPNT003Upfront payment represents a 111% premium to Opiant's closing share price of November 11, 2022, and 99% premium to Opiant's 30-day volume-weighted average share price; total consideration, inclusive of potential CVR payments, represents a premium of up to 195% and 178%, respectivelyAcquisition will expand Indivior's portfolio of addiction therapies and leverage its expertise and resources to maximize
Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well-Suited to Confront Illicit Synthetic Opioids Like Fentanyl Potential Annual OPNT003 Net Revenue of $150 Million to $250 Million Acquisition Expected to be Accretive to Earnings after the Second Full Year of Launch of OPNT003 Indivior to Host Investor Call at 8:00 am U.S. Eastern Today RICHMOND, Va., Nov. 14, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") and Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) ("Opiant") today announced that the companies have entered
SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022. The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13732765. To access the live webcast, please visit h
Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press
CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV). Following the expiration of the waiti
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute that enables the FTC and Department of Justice (DOJ) to review proposed merger transactions by requiring the parties to observe a waiting period before closing their transaction. Completion of the tr
Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. "We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board. Their collective life sciences experience will be invaluable as we advance through several key product development inflection points in the com
SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin